Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial - Lavigne-Lissalde, G; Aya, A G; Mercier, F J (J Thromb Haemost, 2015)
, et al.